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Purpose: This study evaluated the feasibility, efficacy, and durability of a specific aortomonoiliac endograft for the
treatment of abdominal aortic aneurysm (AAA) during a midterm follow-up.
Methods: From January 2002 until November 2008, 106 patients (6 women; mean age, 73.37 7.39 years) were treated
for an AAA using an EndoFit aortomonoiliac graft (LeMaitre Vascular, Burlington, Mass). All procedures were elective.
Results: Mean follow-up was 34.9 months (SD, 20.08; range, 2-81 months). Long-term data (follow-up >60 months)
were available for nine patients, none of which reported any vascular or procedure related complications. Three of the 106
patients (2.83%) died during early follow-up (<30 days); eight died during late follow-up (7.54%). Endograft infection
developed in two patients (1.88%), and an aortoduodenal fistula developed in two (1.88%). Also observed were 15 type
II (14.15%) and three type I (2.83%) endoleaks. Femorofemoral bypass thrombosis was detected in two patients (1.88%).
Conclusion: In this retrospective analysis, the aortomonoiliac configuration for elective AAA repair was proven to be safe
and efficacious. Midterm and long-term follow-up results in this series compare well with previously reported results for
AAA endografting using both bifurcated and aortomonoiliac endoprostheses. ( J Vasc Surg 2009;50:8-14.)Endovascular repair (EVAR) of abdominal aortic aneu-
rysms (AAAs) is feasible, efficacious, and has considerable
short-term benefits compared with conventional open sur-
gery, including shorter duration of operation, reduced
blood loss, shorter length of hospital and intensive care unit
stay, improved quality of life, and lower 30-day mortality
and morbidity rates. Midterm results of EVAR are suffi-
ciently encouraging to justify the choice of the proce-
dure1-8; however, the long-term verdict is still unclear.9-15
Endografting with a bifurcated endoprosthesis is con-
traindicated in certain patients due to various anatomic
restrictions. In those patients, the deployment of an aorto-
monoiliac endograft, followed by a femorofemoral cross-
over bypass, could overcome the anatomic limitations and
successfully exclude the aortic pathology, therefore avoid-
ing open surgical repair.16-24 Several reports have proved
that the aortomonoiliac configuration is both feasible and
efficacious.16-24 The short-term results are comparable to
those that have been reported for bifurcated endoprosthe-
ses, and the patency of the unavoidable extra-anatomical
femorofemoral bypass is as high as 99%.16-24 Most series,
however, do not provide long-term data and do not ex-
clude patients treated for a ruptured AAA. In addition,
most reports include patients treated with a variety of
aortomonoiliac endografts, which further affects the ability
to reach a definite conclusion.
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8This retrospective report analyses the results of elective
endovascular grafting for the exclusion of AAAs using a
specific endoprosthesis during a mean follow-up of 35
months. Long-term data for follow-up 60 months were
available in nine patients.
METHODS
Patient selection. The clinical database of our depart-
ment, located in a tertiary hospital, was retrospectively
interrogated to identify all patients who had undergone
elective endovascular aneurysm repair (EVAR) of an AAA
between January 2002 and November 2008 using the
EndoFit aortomonoiliac endoprosthesis (LeMaitre Vascu-
lar, Burlington, Mass), followed by a femorofemoral cross-
over bypass. The primary indication for EVAR was an AAA
transverse diameter5 cm or a rapidly increasing sac if5
cm. Any symptomatic AAA was also eligible for EVAR.
Ruptured AAAs were not included in this series.
The primary indications for EVAR with the aorto-
monoiliac configuration were the following:
1. narrow terminal aorta, defined as a transverse diameter
15 mm;
2. contralateral common iliac artery angle 90° from the
longitudinal axis of the aneurysm;
3. obstructed contralateral common iliac artery;
4. concomitant ecstatic or frankly aneurysmal bilateral
common iliac arteries, unless the patient had indispens-
able internal iliac arteries;
5. Conversion to the aortomonoiliac configuration while
deploying a bifurcated endograft due to impossible con-
tralateral limb catheterization.
Relative indications for EVAR with the aortomonoiliac
configuration were a heavily calcified contralateral external
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(diameter 5 mm), with or without previous transluminal
angioplasty.
The contraindications for aortomonoiliac graft implan-
tation were the following:
1. proximal neck 10 mm in length (device-dependent);
2. proximal neck32 mm in diameter (device-dependent);
3. proximal neck thrombus 30% of the perimeter;
4. bilateral common iliac arteries 18 mm in diameter with
indispensable internal iliac arteries (device-dependent), de-
fined as nonpatent superiormesenteric artery or nonpatent
Haller’s tripod;
5. excessive bilateral iliac artery tortuosity 90°;
6. excessive bilateral iliac artery calcification; and
7. indispensable inferior mesenteric artery.
General contraindications for every endovascular pro-
cedure were age 18, allergy to contrast medium, coagu-
lopathy, pregnancy or lactation, creatinine level 1.7 mg/
dL, groin infection and connective tissue disease.
Whenever a bifurcated endograft could be implanted,
the aortomonoiliac configuration was avoided because it
involves an extra-anatomic bypass.
Device specifications. The EndoFit self-expanding
stent graft consists of an endoskeleton made of nitinol
stents. The graft has a conical shape (proximal diameter is
larger than the distal diameter). A nitinol bare proximal
stent situated at the top of the endograft enhances proximal
fixation. The first covered stent is doubled to further in-
crease radial force and sealing. The fabric is made of two
layers of expanded polytetrafluoroethylene that are affixed
to the stent skeleton with a thermal process to avoid the
need for fixation sutures. As a result, there is no interface of
the metallic stent with blood, aortic wall, or incoming
wires.
The endograft is inserted through a flexible 18F to 22F
hydrophilic sheath for maximal trackability through tortu-
ous or calcified iliac arteries. The graft comes preloaded on
a sheath or in a separate cartridge from which it can be
loaded on the pre-positioned sheath during the operation.
The proximal diameter of the stent graft is 20 to 36
mm, and the distal diameter is 12 to 26 mm. The EndoFit
is available in lengths of 10 to 20 cm. The EndoFit Oc-
cluder kit was available in sizes of 18 to 34 mm in diameter
and 3.5 cm in length; this allows the operator to occlude
contralateral aneurysmal iliac arteries of up to 30 mm in
diameter (transverse).
Preoperative assessment. Preoperative assessment in-
cluded helical contrast-enhanced computed tomography
angiography (CTA) acquired at 3- or 5-mm intervals with
2- or 3-dimensional reconstruction in all cases. In patients
with impaired renal function, a preoperative magnetic res-
onance angiography (MRA) scan was obtained instead of
contrast-enhanced CTA. The exact dimensions of the prox-
imal and distal landing zones (diameter and length), aortic
and iliac artery tortuosity, and the inner diameters of the
access vessels were determined in all patients preopera-
tively. Digital subtraction angiography (DSA) was usedbefore EVAR in 19 patients (17.92%) to evaluate intermit-
tent claudication or peripheral arterial disease, or both.
Patient comorbidities at admission are summarized in Table I.
Anatomic characteristics are summarized in Table II.
Implantation procedure. All procedures were per-
formed in a fully equipped operating room with the patient
under regional or general anesthesia and fluoroscopic con-
trol using a mobile C-arm (Siremobil 2000; Siemens, Er-
langen, Germany) and iopromide (Ultravist 300, Bayer
Schering Pharma AG, Berlin, Germany), a nonionic con-
trast agent. Standard patient monitoring included electro-
cardiography and arterial pressure. All procedures were
performed by the same team, including two resident vascu-
lar surgeons and an attending vascular surgeon. The im-
plantation procedure is described thoroughly elsewhere.24
In accordance with our department’s standard protocol
for patients undergoing EVAR,25 aspirin and clopidogrel
were administered the day of the procedure. Aspirin was
discontinued on postoperative day 30, and clopidogrel was
continued as a life-long treatment. The patients ambulated
on postoperative day 2. A plain abdominal radiograph was
used to document graft integrity and position. The patient
was usually released on postoperative day 4.
Follow-up. All patients were followed up according to
Table I. Comorbidities upon admission
Comorbidities Patients, No (%)
Coronary disease 53 (50)
Acute myocardial infarction 31 (29.25)
Diabetes mellitus 11 (10.30)
Arterial hypertension 69 (65.09)
Hyperlipidemia 43 (40.57)
Smokers and ex-smokers 87 (82.08)
Chronic renal insufficiency 6 (5.66)
Stroke 3 (2.83)
Chronic obstructive pulmonary disease 18 (16.98)
Hostile abdomen 11 (10.38)
COPD, Chronic obstructive pulmonary disease.
Table II. Anatomic characteristics at admission
Anatomic characteristics Mean (range) No. (%)
Maximal aneurysmal diameter, cm 6.1 (5-12)
Maximal CIA diameter, cm 14 (11-70)
Proximal neck diameter, cm 26 (20-30)
Neck length, cm 15 (10-25)
Neck angulation, degrees 25 (5-72)
Diameter of terminal aorta, cm 24 (4-60)
Excessive contralateral CIA angulation 68 (64)
Contralateral iliac stenosis (6 mm) 24 (23)
Occluded contralateral iliac artery 2 (1.9)
Excessive iliac calcification 41 (39)
Bilateral aneurysmal iliac arteries 8 (7.5)
Neck thrombus 3 (3)
Narrow terminal aorta 26 (25)
Inability to cannulate a bifurcated graft 1 (0.9)
CIA, Common iliac artery.our department’s standard EVAR protocol, which included
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views) and a contrast-enhanced CTA at 1, 6, and 12
months, and annually thereafter. Assessment focused pri-
marily on device migration, proximal neck and aneurysm
sac diameters, and the presence of endoleaks. A full clinical
examination was performed at every follow-up visit. An-
giography was reserved for investigation of suspected en-
doleak or graft occlusion.
Definitions. Technical success was defined as endo-
prosthesis deployment to exclude the aneurysm and achieve
a patent graft without need for a secondary intervention.
Major deployment-related and implant-related complica-
tions, technical success, and all events occurring during
follow-up were analyzed and defined according to Chaikof
et al.26 Endoleaks were classified according to the White-
May definitions27; type II endoleaks were not considered as
major deployment-related complications.26 Postimplant
syndrome was defined as postoperative fever combined
with leukocytosis; it was not considered as a major compli-
cation.26
Statistical analysis. All continuous variables were
tested for normality using the Kolmogorov-Smirnov test.
Normally distributed continuous variables are expressed as
mean standard deviation (SD) or range, where appropri-
ate. Life-table survival analysis was performed for major
complications and death secondary to the procedure (de-
fined as death30 days after the procedure), the implant or
major cardiac complications, or both, including all periop-
erative, early (30 days), and late (30 days) follow-up
events. Also examined were cumulative rates (life-table
analysis) for major complications and death secondary to
the procedure (defined as death 30 days after the proce-
dure) as well as implant or major cardiac complications, or
both. All analyses were performed using the SPSS 13.0
software (SPSS Inc, Chicago, Ill).
RESULTS
Procedural results. Between January 2002 and No-
vember 2008, 106 patients (6 women; mean age, 73.37 
7.39 years) were treated with the EndoFit (LeMaitre Vas-
cular, Burlington, Mass) aortomonoiliac device. Contrain-
dications resulted in the exclusion of 14 patients from
treatment with an aortomonoiliac device. During the same
period, 297 patients were treated for an AAA using a
bifurcated endoprosthesis. A tubular stent graft was used in
55 patients, and 126 patients were offered open repair. The
stent graft was successfully deployed in all patients (100%
technical success). EndoFit extensions were used in 19 of
106 patients (17.92%), either for landing in the external
iliac artery or when the length of the main graft body was
inadequate to reach the distal landing zone. The ipsilateral
internal iliac artery was intentionally occluded in 11 pa-
tients (10.37%) to accomplish safe distal attachment and
sealing (the common iliac artery was aneurysmal in all of
those patients).
Regional anesthesia was used in 103 procedures and
general anesthesia was used in three. According to Ameri-
can Society of Anesthesiologists (ASA) classification,23 49(46.2%) were at class 3 or higher and were thus considered
as being at high surgical risk. There were no perioperative
deaths.
The mean operative time was 114 minutes (range,
82-243 minutes), and the mean fluoroscopy time was 14
minutes (range, 9-48 minutes). The mean amount of con-
trast medium used was 160 mL (range, 80-280 mL).
Perioperative blood transfusion was required in 18 patients
(16.98%), but none required 2 U of blood.
The mean length of hospital stay was 6 days (range,
4-11 days). All patients were monitored in the intensive
care unit (ICU) postoperatively for at least 2 hours, with a
mean ICU stay of 4 hours (range, 2-72 hours), before
being transferred to the surgical ward.
Early follow-up (<30 days). Three deaths (2.83%)
occurred during early follow-up. An 88-year-old man with
chronic renal failure and cardiac insufficiency died on post-
operative day 2 of acute myocardial infarction. Two other
men, 78 and 80 years old, respectively, died of acute
myocardial infarction after discharge from hospital and
30 days after the operation. One patient (0.94%) had a
nonfatal acute myocardial infarction on postoperative
day 2.
A 68-year-old-man (0.94%) treated for an anastomotic
AAA was diagnosed with an aortoduodenal fistula 18 days
after the grafting procedure. A blood culture was also
found positive for Bacteroides fragilis. The patient was
offered emergency laparotomy. Cultures from the ex-
tracted graft revealed Stenotrophomonas maltophilia. The
patient was admitted to the ICU, where he remained
hospitalized for 9 days. The patient fully recovered and was
in good condition 4 years after the procedure.
Two endoleaks were observed during early follow-up.
A proximal type I endoleak (0.94%) was identified at 1
month and was treated with a proximal cuff. A type II
endoleak (0.94%) was discovered on postoperative day 30,
but no further action was taken. The patient remained
under surveillance and has reported no further complica-
tions related to the procedure.
Femorofemoral graft thrombosis occurred in one pa-
tient (0.94%) during early follow-up due to insufficient
inflow caused by a residual stenosis of the endograft. The
deficit was treated immediately with thrombectomy of the
PTFE graft and balloon dilatation of the EndoFit graft.
A wound hematoma occurred in 10 patients and was
treated conventionally. Superficial infection and lymphor-
rhea were identified in eight patients (7.54%) and were
treated conventionally. All patients with clinical evidence of
a superficial infection or wound hematoma, or both, had an
indium white blood cells scan to exclude further infection
of the endoluminal devices. The results of all scans were
negative. No further infection-related sequelae were noted
in these patients during follow-up. Postimplant syndrome
developed in 14 patients (13.2%) and was treated conven-
tionally with nonsteroidal anti-inflammatory drugs. No
graft migration, paraplegia, distal embolization, or any
other serious complications were observed during early
follow-up.
ollow
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34.94 months (SD, 20.08; range, 2-81 months). Fourteen
patients were lost to late follow-up. Long-term follow-up
data 60 months were available for nine patients, none of
whom was lost to follow-up. One patient died 2 years after
the operation of causes not related to the procedure; how-
ever, no vascular or procedure related complications were
observed after postoperative day 30 within this patient
group. Eight deaths (7.54%) have occurred during late
follow-up: 1 patient (0.94%) died of lower gastrointestinal
bleeding 20 months after aortomonoiliac graft implanta-
tion and 14 months after he had been treated for a second-
ary aortoduodenal fistula, 3 (3.77%) died of acute myocar-
dial infarction (classified as major cardiac complication), 2
(1.88%) died of unknown causes (classified as indetermi-
nate death), and 2 (1.88%) died of cancer.
A 60-year-old man (0.94%) was diagnosed with an
aortoduodenal fistula and graft infection at postoperative
month 6. No evident defects were noted in the explanted
graft. The patient recovered, but eventually died 14
months later after being admitted to another institution
because of lower gastrointestinal bleeding. The two pa-
tients with aortoduodenal fistulas and graft infection are
being discussed analytically elsewhere.28
A distal type I endoleak was observed at postoperative
month 12 in one patient and was treated with an EndoFit
extension graft; no further complications have occurred in
this patient. Another distal type I endoleak was detected in
another patient at the 12-month follow-up abdominal CT
scan and was treated with a balloon-expanding (Parodi
type) extension; the patient has remained under surveil-
lance ever since, and no further procedure related compli-
cations have been reported. One patient was admitted at
Fig 1. Life-table analysis is shown for freedom from de
secondary to a major cardiac complication throughout fpostoperative month 6 reporting intermittent claudication,and the subsequent imaging investigation disclosed a
thrombosis of the femorofemoral bypass. The deficit was
treated with thrombectomy of the PTFE graft; the patient
has not reported further vascular complications.
A stenosis of the femorofemoral bypass graft was ob-
served in one patient at postoperative month 12; the pa-
tient was treated conservatively, and no further vascular
complications have been observed.
Type II endoleaks were observed in 14 patients (13.2%)
during late follow-up (30 days), but none underwent
reoperations; they all remained under normal follow-up
surveillance. Four patients (3.77%) sustained a nonfatal
acute myocardial infarction. The cumulative rates at 81
months were 12% for procedure related death (Fig 1) and
29% for major complications (Fig 2). Late follow-up out-
comes are summarized in Table III. Changes in AAA
volume and AAA diameter during follow-up could not be
reported because we lacked postoperative CT scans that
included 1-mm slices.
DISCUSSION
This report provides evidence that the midterm and
long-term results of endovascular grafting using the aorto-
monoiliac EndoFit stent graft compare well with the results
that have been reported so far for various aortomonoiliac
and bifurcated endoprostheses or open surgical repair. Our
initial results with the specific aortomonoiliac graft were
reported 3 years ago and included 39 patients. The median
follow-up was 14 months.24
The aortomonoiliac configuration was initially re-
ported by May et al,14 Parodi et al,22 and Marin et al23
using a balloon-expandable stent graft (proximal graft af-
fixation) and a distal surgical anastomosis of the graft to the
lated to the procedure or the implant, or both, or death
-up.ath reipsilateral iliac or common femoral artery. Since then, sev-
for fr
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to—the specific configuration, claiming poor femorofemo-
ral bypass patency rates, basing their assertion is based on
various reports citing 5-year patency rates of 35% to
92%.29-39 However, aortomonoiliac endografting, fol-
lowed by a femorofemoral crossover bypass, is applied in
patients with aneurysmal disease who typically do not
present with obstructive peripheral arterial disease.
Moreover, most registries relative to patency rates of
femorofemoral crossover bypass as an adjunct to aorto-
monoiliac endografting have reported high patency rates of
up to 91% at 3 years40 and 99% at 4 years.41 In this series,
the overall patency rate of the femorofemoral bypass was
98.11%. These results are well comparable with iliac leg
thrombosis rates for bifurcated modular endoprostheses.42
The primary patency rate was 97.5%, and the secondary
patency rate was 100% in our initial report.24 In this series,
thrombosis of the femorofemoral bypass developed in two
of 106 patients (1.88%). Our technical success rate was
100%, which compares favorably with the reported rates of
94% to 99% for various other endografts.42-51
An interesting observation during follow-up 60
months is that no procedure related complication devel-
Fig 2. Life-table analysis is shown
Table III. Outcome for late follow-up (30 days)
Event Patients, No. (%)
Death 8 (7.54)
Endoleak type I 2 (1.88)
Endoleak type II 14 (13.20)
Aortoduodenal fistula  infection 1 (0.94)
Acute myocardial infarction 4 (3.77)
Bypass thrombosis or stenosis 2 (1.88)oped after postoperative day 30 in any of the patients forwhom long-term data were available. Endoleak from the
site of the occluded iliac artery may also theoretically occur
when an aortomonoiliac graft is used; however, this com-
plication was not documented in our patient group.
Recognized advantages of the aortomonoiliac configu-
ration include the ease of device deployment as well as the
absence of modular interface requirements and their poten-
tial pitfalls. The aortomonoiliac configuration is particularly
favored in patients who present with ruptured aneurysms
because the rapid exclusion of the aneurysm sac is of major
importance to avoid a fatal outcome. The aortomonoiliac
graft is deployed in considerably less time because con-
tralateral stump cannulation and deployment of a contralat-
eral leg is not needed.
In some AAAs, implantation of a bifurcated endopros-
thesis may not be feasible due to anatomic restrictions such
as a narrow terminal aorta and a tortuous, narrow, or
obstructed contralateral iliac artery.49 In this series, the
aortomonoiliac configuration was reserved for relatively
unfavorable aortic anatomies, such as aneurysm neck angu-
lation, narrow terminal aorta or complex iliac artery anat-
omy, or both, as well as for patients who were unfit for open
surgical repair. One would, therefore, expect a potential
increase in early and late complication rates, which has not
been documented. The aortomonoiliac configuration in
our department has been applied (elective EVAR) to about
18% of the patients who eventually underwent elective
EVAR for an AAA. This is mainly due to the anatomic
limitations that we often encounter in patients who are
being considered for EVAR, possibly attributable to our
department being situated in a tertiary hospital.
A major complication seen twice in this series was the
development of an aortoduodenal fistula; however, no de-
fects were noted in the extracted graft. Both patients have
eedom from major complications.been discussed thoroughly elsewhere.28One of the patients
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had undergone open infrarenal AAA repair with an aor-
toaortic Dacron graft. We assume that the aortomonoiliac
graft infection could be attributed to preexisting infection
of the Dacron graft that was underestimated at the time of
endovascular repair.
The limitations of this report include its retrospective
nature and that 14 patients were lost to follow-up. How-
ever, the relatively large number of patients involved (106),
given that the aortouniiliac configuration is usually reserved
for aneurysm rupture and not elective AAA repair, and the
duration of the follow-up, enable for relatively safe conclu-
sions to be made.
CONCLUSIONS
This report provides evidence that the aortomonoiliac
configuration using the specific endoprosthesis is a safe
procedure over the midterm and long-term and compares
well with the results of repair with bifurcated endoprosthe-
ses that have been published.4,9,42-51 In any case, the
technique incorporates an extra-anatomic bypass and
should be reserved for unfavorable anatomies and patients
unfit for open repair.
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